1IC
PBE icon

1919 Investment Counsel’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

1919 Investment Counsel’s Portfolio PBE Stock Details PBE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$37K Hold
800
– – ﹤0.01% 732
2014
Q2 		$35K Hold
800
– – ﹤0.01% 747
2014
Q1 		$34K Sell
800
-300
-27% -$12.8K ﹤0.01% 732
2013
Q4 		$41K Buy
1,100
+300
+38% +$10.8K ﹤0.01% 714
2013
Q3 		$29K Buy
+800
New +$26.5K ﹤0.01% 754

Other funds holding PBE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
TAM
Trillium Asset Management Boston, Massachusetts $3.01B AUM 19.96% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SAM
SignalPoint Asset Management Springfield, Missouri $411M AUM 23.81% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

1919 Investment Counsel's PBE Position: Q3 2014 in Review

1919 Investment Counsel held its Invesco Biotechnology & Genome ETF (PBE) position steady in Q3 2014 at 800 shares worth $37K. The position accounts for ﹤0.01% of the portfolio, ranked #732.

1919 Investment Counsel first reported a position in PBE in Q3 2013 and has held it in 5 quarters since. The position peaked at $41K in Q4 2013. 70 funds tracked by Wall St. Rank hold PBE as of Q3 2014.

  • 1919 Investment Counsel held 800 shares of Invesco Biotechnology & Genome ETF worth $37K as of Q3 2014.
  • 1919 Investment Counsel left its Invesco Biotechnology & Genome ETF share count unchanged in Q3 2014.
  • Invesco Biotechnology & Genome ETF made up ﹤0.01% of 1919 Investment Counsel's portfolio in Q3 2014, its #732 holding.
  • 1919 Investment Counsel first reported a position in Invesco Biotechnology & Genome ETF in Q3 2013 and has held it in 5 quarters since.
  • 1919 Investment Counsel's Invesco Biotechnology & Genome ETF position peaked at $41K in Q4 2013.
  • 70 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2014.

Based on 1919 Investment Counsel's 13F filing for Q3 2014, filed 14 Nov 2014.